Literature DB >> 15309693

Mitral regurgitation in patients with advanced systolic heart failure.

Jeetendra B Patel1, Daniel D Borgeson, Marion E Barnes, Charanjit S Rihal, Richard C Daly, Margaret M Redfield.   

Abstract

BACKGROUND: Mitral regurgitation (MR) may develop in patients with advanced systolic congestive heart failure (CHF) without organic mitral valve disease and contribute to worsening symptoms and survival. Surgical mitral annuloplasty improves symptoms in patients with advanced CHF, and percutaneous approaches to mitral annuloplasty are being developed. Our objective was to define the prevalence, clinical correlates, and prognostic implications of functional MR and the use of mitral annuloplasty in patients with advanced systolic CHF evaluated in a heart failure clinic. METHODS AND
RESULTS: We reviewed clinical, echocardiographic, and survival data from all patients with advanced systolic CHF (New York Heart Association class III or IV; ejection fraction </=35%) resulting from ischemic or idiopathic cardiomyopathy who were evaluated at our heart failure clinic between January 1996 and September 2001. Of 716 patients with advanced CHF, 558 had satisfactory baseline echocardiograms performed at our institution. Among these patients, MR was severe in 24 (4.3%), moderate-severe in 70 (12.5%), moderate in 122 (21.9%), mild-moderate in 66 (11.8%), mild in 218 (39.1%), and absent or present as only a trace in 58 (10.4%). The severity of MR was confirmed by quantitative analysis in 72% of patients with hemodynamically significant MR (more than moderate). The severity of MR correlated with the severity of systolic dysfunction (P <.001), ventricular dilatation (P <.03), atrial dilatation (P <.001), diastolic dysfunction (P <.001), and pulmonary hypertension (P <.001). Coexistent severe or moderate-severe tricuspid regurgitation was present in 25% of patients with hemodynamically significant MR. Patients with hemodynamically significant MR had higher mortality (P=.03) but not when controlling for age, sex, cause, New York Heart Association class, and ejection fraction (P=.95). Only 3 patients subsequently underwent mitral valve repair.
CONCLUSION: Among patients with advanced CHF, hemodynamically significant MR is common. The severity of MR did not provide independent prognostic information in this group recognized to have uniformly high mortality.

Entities:  

Mesh:

Year:  2004        PMID: 15309693     DOI: 10.1016/j.cardfail.2003.12.006

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  48 in total

1.  Right ventricular function in heart failure with preserved ejection fraction: a community-based study.

Authors:  Selma F Mohammed; Imad Hussain; Omar F AbouEzzeddine; Omar F Abou Ezzeddine; Hiroyuki Takahama; Susan H Kwon; Paul Forfia; Véronique L Roger; Margaret M Redfield
Journal:  Circulation       Date:  2014-11-12       Impact factor: 29.690

Review 2.  Surgical approach to mitral regurgitation in chronic heart failure: when is it an option?

Authors:  Juan A Crestanello
Journal:  Curr Heart Fail Rep       Date:  2012-03

3.  Deep sedation versus general anesthesia in percutaneous edge-to-edge mitral valve reconstruction using the MitraClip system.

Authors:  Suzanne de Waha; Joerg Seeburger; Joerg Ender; Steffen Desch; Ingo Eitel; Adrian Reinhardt; Janine Pöss; Georg Fuernau; Thilo Noack; Denis Rouven Merk; Gerhard Schuler; Hans-Hinrich Sievers; Friedrich-Wilhelm Mohr; Holger Thiele
Journal:  Clin Res Cardiol       Date:  2015-12-18       Impact factor: 5.460

4.  Oxidation and tyrosine phosphorylation: synergistic or antagonistic cues in protein tyrosine phosphatase.

Authors:  P Chiarugi; M L Taddei; G Ramponi
Journal:  Cell Mol Life Sci       Date:  2005-05       Impact factor: 9.261

Review 5.  Current and novel cardiac support therapies.

Authors:  Bodh I Jugdutt
Journal:  Curr Heart Fail Rep       Date:  2009-03

Review 6.  [Coronary sinus devices for treatment of functional mitral valve regurgitation. Solution or dead end?].

Authors:  H Degen; T Schneider; J Wilke; M Haude
Journal:  Herz       Date:  2013-08       Impact factor: 1.443

Review 7.  Ischemic and functional mitral regurgitation in heart failure: natural history and treatment.

Authors:  Mina M Benjamin; Robert L Smith; Paul A Grayburn
Journal:  Curr Cardiol Rep       Date:  2014-08       Impact factor: 2.931

8.  Characterization of the mechanical properties of the coronary sinus for percutaneous transvenous mitral annuloplasty.

Authors:  Thuy Pham; Wei Sun
Journal:  Acta Biomater       Date:  2010-06-01       Impact factor: 8.947

9.  [Mitral regurgitation in heart failure. Surgical therapy].

Authors:  H Aubin; H Kamiya; A Lichtenberg
Journal:  Herz       Date:  2013-03       Impact factor: 1.443

Review 10.  Devices in the management of advanced, chronic heart failure.

Authors:  William T Abraham; Sakima A Smith
Journal:  Nat Rev Cardiol       Date:  2012-12-11       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.